Drug intelligence / Profile preview

MK-2248

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-2248 is an investigational small molecule antiviral drug developed by Merck Sharp & Dohme. It was studied primarily for the treatment of hepatitis C virus (HCV) infection. The drug reached phase 1 clinical trials, where it was evaluated for safety, pharmacokinetics, and pharmacodynamics in subjects with chronic hepatitis C. The primary goal in these studies was to identify a safe dose that could achieve at least a 3 log10 reduction in viral load from baseline. Its precise mechanism of action has not been publicly defined or disclosed[1][2][3].

Beyond the preview

Go deeper on MK-2248.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-2248.